Empowered Patient Podcast

Dr. Costas Hadjipanayis, Director of Neurosurgical Oncology for Mount Sinai Beth Israel Hospital discusses his experience working with the advanced robotically-controlled digital microscope, Modus V, from Synaptive Medical and how this technology was used recently to successfully remove a 19-year old woman's rare brain tumor. Dr. H talks about the advantages to using this technology prior to surgery and during surgery, and how doctors need to think about embracing new devices and techniques to more accurately address medical challenges.

@SynaptiveMed

#BrainSurgery #Neurosurgery #PrecisionMedicine #RoboticSurgery #ModusV

Synaptive Medical

Listen to the podcast here.

Dr. Costas Hadjipanayis, Director of Neurosurgical Oncology for Mount Sinai Beth Israel Hospital discusses his experience working with the advanced robotically-controlled digital microscope, Modus V, from Synaptive Medical and how this technology was used recently to successfully remove a 19-year old woman's rare brain tumor. Dr. H talks about the advantages to using this technology prior to surgery and during surgery, and how doctors need to think about embracing new devices and techniques to more accurately address medical challenges.

@SynaptiveMed

#BrainSurgery #Neurosurgery #PrecisionMedicine #RoboticSurgery #ModusV

Synaptive Medical

Download the transcript here.

Isaac Israel, CEO, Kitov Pharmaceuticals talks about how the development of new cancer treatments is an active and rapidly changing field and how Kitov is focusing on making cancer treatments more effective for patients. They are developing combination therapies that can help overcome cancers' ability to develop resistance to treatment. Kitov is working on two innovative cancer treatments soon to be advanced to clinical trials.

#oncology #immunoOncology

Kitov Pharmaceuticals

Listen to the podcast here.

Isaac Israel, CEO, Kitov Pharmaceuticals talks about how the development of new cancer treatments is an active and rapidly changing field and how Kitov is focusing on making cancer treatments more effective for patients. They are developing combination therapies that can help overcome cancers' ability to develop resistance to treatment. Kitov is working on two innovative cancer treatments soon to be advanced to clinical trials.

#oncology #immunoOncology

Kitov Pharmaceuticals

Download the transcript here.

Gilead Raday, COO, Redhill Biopharma, a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases talks about the growing problem of antibiotic resistance and the challenges this presents treating H. pylori infections, which affects about half of the global population. Redhill is working to bring Talicia, a new treatment for H. pylori to market potentially this year giving patients a new effective option for H. pylori infection.

#RDHL $RDHL #Hpylori #IBD #GI

@RedHillBio

Redhillbio.com

Listen to the podcast here.

Gilead Raday, COO, Redhill Biopharma, a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases talks about the growing problem of antibiotic resistance and the challenges this presents treating H. pylori infections, which affects about half of the global population. Redhill is working to bring Talicia, a new treatment for H. pylori to market potentially this year giving patients a new effective option for H. pylori infection.

#RDHL $RDHL #Hpylori #IBD #GI

@RedHillBio

Redhillbio.com

Download the transcript here.

Paul Kohlhaas, Founder, Molecule is passionate about creating a network for the decentralization of the process of researching new molecules and developing new molecular compounds using blockchain to track and reward all those who participate. With the current pharma innovation crisis and rising costs of drug development, new methods are needed to break down silos and overcome challenges of drug resistance and treating rare diseases.

@molecule_to

Molecule.to

Download the transcript here.

Paul Kohlhaas, Founder, Molecule is passionate about creating a network for the decentralization of the process of researching new molecules and developing new molecular compounds using blockchain to track and reward all those who participate. With the current pharma innovation crisis and rising costs of drug development, new methods are needed to break down silos and overcome challenges of drug resistance and treating rare diseases.

@molecule_to

Molecule.to

Listen to the podcast here.

Dr. Nerissa Kreher, Chief Medical Officer, Tiburio discusses the company's lead asset, TBR-760 as a novel treatment option for patients with non-functioning pituitary adenomas (NFPA), which are rare neuroendocrine tumors located in the pituitary gland. She also speaks about the challenges facing patients even after surgical or radiation treatments for these pituitary tumors. Download the transcript. Listen to the podcast here.

@TiburioT

#neuroendocrine #pituitaryadenoma #chiefmedicalofficer #raredisease #NFPA

Tiburio Therapeutics

Dr. Nerissa Kreher, Chief Medical Officer, Tiburio discusses the company's lead asset, TBR-760 as a novel treatment option for patients with non-functioning pituitary adenomas (NFPA), which are rare neuroendocrine tumors located in the pituitary gland. She also speaks about the challenges facing patients even after surgical or radiation treatments for these pituitary tumors.

@TiburioT

#neuroendocrine #pituitaryadenoma #chiefmedicalofficer #raredisease #NFPA

Tiburio Therapeutics

Download the PDF file of the interview here.